M. Matin, A. Asilian, Samaneh Mozafar Poor, Elaheh Haftbaradaran, A. Feily
{"title":"利妥昔单抗治疗皮肤淋巴增生症3例报告","authors":"M. Matin, A. Asilian, Samaneh Mozafar Poor, Elaheh Haftbaradaran, A. Feily","doi":"10.35248/2684-124X.19.4.150","DOIUrl":null,"url":null,"abstract":"Benign Cutaneous Lymphoid Hyperplasia (CLH) is a B-cell pseudolymphoma of an unknown origin. The face is the most affected site in CLH. This report presents the cases of 3 patients with CLH who were treated with rituximab. \n \nIt is a hypothesis that rituximab is useful for treating resistant-to-relapsing forms of CLH that do not respond to previous therapies but must be checked with appropriate designs research.","PeriodicalId":92997,"journal":{"name":"Dermatology case reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of Cutaneous Lymphoid Hyperplasia with Rituximab: A Case Report of 3 Patients\",\"authors\":\"M. Matin, A. Asilian, Samaneh Mozafar Poor, Elaheh Haftbaradaran, A. Feily\",\"doi\":\"10.35248/2684-124X.19.4.150\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Benign Cutaneous Lymphoid Hyperplasia (CLH) is a B-cell pseudolymphoma of an unknown origin. The face is the most affected site in CLH. This report presents the cases of 3 patients with CLH who were treated with rituximab. \\n \\nIt is a hypothesis that rituximab is useful for treating resistant-to-relapsing forms of CLH that do not respond to previous therapies but must be checked with appropriate designs research.\",\"PeriodicalId\":92997,\"journal\":{\"name\":\"Dermatology case reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2684-124X.19.4.150\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2684-124X.19.4.150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Treatment of Cutaneous Lymphoid Hyperplasia with Rituximab: A Case Report of 3 Patients
Benign Cutaneous Lymphoid Hyperplasia (CLH) is a B-cell pseudolymphoma of an unknown origin. The face is the most affected site in CLH. This report presents the cases of 3 patients with CLH who were treated with rituximab.
It is a hypothesis that rituximab is useful for treating resistant-to-relapsing forms of CLH that do not respond to previous therapies but must be checked with appropriate designs research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
